Table 3.
Se‐treated group | Control group | p value | Interaction p value | ||
---|---|---|---|---|---|
N | Total | 43 | 47 | ||
Outcomes | Subgroup | ||||
ΔTPOAb, IU/ml | Se level | 0.113 | |||
S1 < 80 μg/L (n = 49) |
−37.1 (n = 25) (−121.7, 0.0) |
2.9 (n = 24) (−19.6, 33.7) |
0.001 | ||
S2 ≥ 80 μg/L (n = 41) |
−6.45 (n = 18) (−50.9, 0.0) |
−1.2 (n = 23) (−18.1, 2.5) |
0.180 | ||
Thyroid function | 0.054 | ||||
EHT (n = 61) |
−6.8 (n = 27) (−47.1, 0.0) |
−0.5 (n = 34) (−18.8, 32.6) |
0.077 | ||
SHT (n = 29) |
−86.5 (n = 16) (−195.7, −28.3) |
0.0 (n = 13) (−12.7, 12.8) |
0.003 | ||
ΔTGAb, IU/ml | Se level | 0.687 | |||
S1 <80 μg/L (n = 49) |
−43.3 (n = 25) (−114.4, −3.4) |
30.5 (n = 24) (−18.8, 73.4) |
0.002 | ||
S2 ≥ 80 μg/L (n = 41) |
−56.5 (n = 18) (−375.1, 22.7) |
12.7 (n = 23) (−36.5, 95.6) |
0.098 | ||
Thyroid function | 0.853 | ||||
EHT (n = 61) |
−62.3 (n = 27) (−181.8, −4.2) |
18.1 (n = 34) (−32.9, 77.3) |
0.004 | ||
SHT (n = 29) |
−21.3 (n = 16) (−126.1, 27.7) |
26.6 (n = 13) (−5.3, 112.8) |
0.039 | ||
ΔTSH, mIU/L | Se level | 0.116 | |||
S1 < 80 μg/L (n = 49) |
−0.63 (n = 25) (−2.83, 0.27) |
0.49 (n = 24) (1.11, 0.12) |
0.001 | ||
S2 ≥ 80 μg/L (n = 41) |
−0.01 (n = 18) (−0.67, 0.52) |
0.29 (n = 23) (−0.91, 1.74) |
0.293 | ||
Thyroid function | 0.003 | ||||
EHT (n = 61) |
0.01 (n = 27) (−0.61, 0.68) |
0.38 (n = 34) (−0.05, 1.06) |
0.079 | ||
SHT (n = 29) |
−2.5 (n = 16) (−4.02, −0.28) |
1.91 (n = 13) (−1.36, 2.76) |
0.002 |
Δ = value after treatment − baseline value.
Abbreviations: EHT, euthyroid Hashimoto thyroiditis; S1: Se <80 μg/L; S2: >80 μg/L; Se, selenium; SHT, subclinical Hashimoto thyroiditis; TgAb, antithyroglobulin antibodies; TPOAb, antithyroid peroxidase antibodies; TSH, thyroid stimulating hormone.